Loading...

SNSE SENSEI BIOTHERAPEUTICS INC Expansion Plans 8-K Filing

SNS

SNS

SENSEI BIOTHERAPEUTICS INC

(SNSE)

2025 8-K

Financial Results Update

Strategic Review Announcement

Clinical Trial Update

Earnings Releases

Voluntary Delisting

Reverse Stock Split

Financial Results

Clinical Trial Update

Stock Delisting Notice

Financial Results

Board Resignation

Management Change

Earnings Reports

Resignation of Director

Presentation Update

Clinical Data Presentation

Financial Results Announcement

Consulting Agreement with F...

Resignation of CFO

Stockholder Rights Agreemen...

Financial Results Announcement

Resignation and Appointment

Presentation Update

Financial Results Announcement

Rejection of Proposal

Clinical Data and Presentat...

Earnings Report

Investor Conferences

Amendment to Rights Agreement

Purchase Agreement for Stoc...

Earnings Reports

Presentation Update

Earnings Reports

Presentation Update

Nomination of Board Candidates

Stockholder Rights Plan

Bonuses paid in RSUs

External Links:

On October 17, 2025, Sensei Biotherapeutics reported new clinical results showing durable progression-free survival data for their drug Solnerstotug in PD-(L)1 resistant tumors, highlighted during the ESMO Congress 2025. The company also mentioned a related webcast and updated corporate presentation.

AI Assistant

SENSEI BIOTHERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.